BRPI0921063A2 - Composto, e, composição agonística para o receptor de melanocortina. - Google Patents
Composto, e, composição agonística para o receptor de melanocortina.Info
- Publication number
- BRPI0921063A2 BRPI0921063A2 BRPI0921063-6A BRPI0921063A BRPI0921063A2 BR PI0921063 A2 BRPI0921063 A2 BR PI0921063A2 BR PI0921063 A BRPI0921063 A BR PI0921063A BR PI0921063 A2 BRPI0921063 A2 BR PI0921063A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- melanocortin receptor
- receptor agonistic
- agonistic composition
- composition
- Prior art date
Links
- 102000004378 Melanocortin Receptors Human genes 0.000 title 1
- 108090000950 Melanocortin Receptors Proteins 0.000 title 1
- 230000001270 agonistic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20080112403 | 2008-11-12 | ||
KR10-2008-0112403 | 2008-11-12 | ||
PCT/KR2009/006568 WO2010056022A2 (en) | 2008-11-12 | 2009-11-10 | Melanocortin receptor agonists |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0921063A2 true BRPI0921063A2 (pt) | 2015-08-25 |
BRPI0921063B1 BRPI0921063B1 (pt) | 2021-03-16 |
BRPI0921063B8 BRPI0921063B8 (pt) | 2021-05-25 |
Family
ID=42165801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0921063A BRPI0921063B8 (pt) | 2008-11-12 | 2009-11-10 | composto, e, composição agonística para receptor de melanocortina |
Country Status (26)
Country | Link |
---|---|
US (4) | US8288386B2 (pt) |
EP (1) | EP2350060B1 (pt) |
JP (1) | JP5399506B2 (pt) |
KR (1) | KR101141976B1 (pt) |
CN (1) | CN102282141B (pt) |
AR (1) | AR074109A1 (pt) |
AU (1) | AU2009314827B2 (pt) |
BR (1) | BRPI0921063B8 (pt) |
CA (1) | CA2742248C (pt) |
CL (1) | CL2011001073A1 (pt) |
CO (1) | CO6362006A2 (pt) |
CR (1) | CR20110250A (pt) |
EA (1) | EA019146B1 (pt) |
EC (1) | ECSP11011026A (pt) |
GE (1) | GEP20135850B (pt) |
IL (1) | IL212468A0 (pt) |
MA (1) | MA32774B1 (pt) |
MX (1) | MX2011004583A (pt) |
NZ (1) | NZ592512A (pt) |
PE (1) | PE20110684A1 (pt) |
TN (1) | TN2011000222A1 (pt) |
TW (1) | TWI389903B (pt) |
UA (1) | UA99555C2 (pt) |
UY (1) | UY32238A (pt) |
WO (1) | WO2010056022A2 (pt) |
ZA (1) | ZA201103154B (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA99555C2 (en) * | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
WO2012100342A1 (en) | 2011-01-27 | 2012-08-02 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
PT3539551T (pt) | 2011-12-29 | 2021-11-04 | Rhythm Pharmaceuticals Inc | Método de tratamento de distúrbios associados ao recetor de melanocortina-4 em portadores heterozigóticos |
JP6235560B2 (ja) | 2012-04-25 | 2017-11-22 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | (3,4−ジクロロ−フェニル)−((s)−3−プロピル−ピロリジン−3−イル)−メタノン塩酸塩及び製造方法 |
CN103420981A (zh) * | 2012-05-21 | 2013-12-04 | 中国医学科学院药物研究所 | 含有取代吡咯烷基的硫代吗啉类化合物 |
SG10202101510XA (en) | 2015-09-30 | 2021-03-30 | Rhythm Pharmaceuticals Inc | Method of treating melanocortin-4 receptor pathway-associated disorders |
WO2019195756A1 (en) | 2018-04-06 | 2019-10-10 | Rhythm Pharmaceuticals, Inc. | Compositions for treating kidney disease |
JP7467510B2 (ja) * | 2019-11-07 | 2024-04-15 | エルジー・ケム・リミテッド | メラノコルチン-4受容体アゴニスト |
PE20240124A1 (es) | 2020-10-29 | 2024-01-22 | Lg Chemical Ltd | Forma cristalina ii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma |
EP4219475A4 (en) | 2020-10-29 | 2024-03-13 | Lg Chem, Ltd. | CRYSTAL FORM IV OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PROCESS FOR PRODUCTION THEREOF |
PE20240048A1 (es) | 2020-10-29 | 2024-01-09 | Lg Chemical Ltd | Forma cristalina i del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma |
US20230382895A1 (en) * | 2020-10-29 | 2023-11-30 | Lg Chem, Ltd. | Crystalline form iii of melanocortin receptor agonist compound and preparation method therefor |
WO2022092908A1 (ko) | 2020-10-29 | 2022-05-05 | 주식회사 엘지화학 | 무정형의 멜라노코르틴-4 수용체 작용제 |
JP2024501829A (ja) | 2020-12-22 | 2024-01-16 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物の結晶形iiiおよびその製造方法 |
EP4249482A4 (en) | 2020-12-22 | 2024-05-15 | Lg Chem, Ltd. | AMORPHOUS MELANOCORTIN RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR |
KR20220090456A (ko) | 2020-12-22 | 2022-06-29 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물의 결정형 i 및 이의 제조방법 |
US20240051944A1 (en) | 2020-12-22 | 2024-02-15 | Lg Chem, Ltd. | Crystalline form ii of melanocortin receptor agonist compound and preparation method therefor |
MX2023007429A (es) * | 2020-12-22 | 2023-07-03 | Lg Chemical Ltd | Uso como agonista selectivo de receptor de melanocortina-4. |
CA3203998A1 (en) * | 2021-01-21 | 2022-07-28 | Hee Dong Park | Use of melanocortin-4 receptor agonist |
TWI826938B (zh) | 2021-02-26 | 2023-12-21 | 南韓商Lg化學股份有限公司 | 黑皮質素-4受體促效劑 |
JP2024518055A (ja) | 2021-05-06 | 2024-04-24 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物の結晶形vおよびその製造方法 |
WO2022235105A1 (ko) | 2021-05-06 | 2022-11-10 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅶ 및 이의 제조방법 |
BR112023022432A2 (pt) | 2021-05-07 | 2024-01-09 | Lg Chemical Ltd | Formas cristalinas iv de sais de ácidos orgânicos de composto agonista do receptor de melanocortina, seus metódos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas |
CN117255787A (zh) | 2021-05-07 | 2023-12-19 | 株式会社Lg 化学 | 黑皮质素受体激动剂化合物的硫酸盐晶体及其制备方法 |
WO2022235107A1 (ko) | 2021-05-07 | 2022-11-10 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물과 바닐린의 공결정 및 이의 제조방법 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6534503B1 (en) | 1998-04-28 | 2003-03-18 | Lion Bioscience Ag | Melanocortin receptor-3 ligands to treat sexual dysfunction |
WO2000074679A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
GB0002059D0 (en) | 2000-01-28 | 2000-03-22 | Melacure Therapeutics Ab | Novel aromatic amines |
CA2403686C (en) | 2000-03-23 | 2010-01-26 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
JP2003527444A (ja) | 2000-03-23 | 2003-09-16 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体 |
GB0019359D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
WO2002015909A1 (en) | 2000-08-23 | 2002-02-28 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
DZ3415A1 (fr) | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
ES2247298T3 (es) | 2001-01-23 | 2006-03-01 | Eli Lilly And Company | Derivados de piperazina y piperidina como agonistas del receptor de melanocortina. |
EP1368339A1 (en) | 2001-01-23 | 2003-12-10 | Eli Lilly & Company | Substituted piperidines/piperazines as melanocortin receptor agonists |
CA2432988A1 (en) | 2001-01-23 | 2002-08-01 | Cristina Garcia-Paredes | Melanocortin receptor agonists |
WO2002067869A2 (en) | 2001-02-28 | 2002-09-06 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
IL157253A0 (en) | 2001-02-28 | 2004-02-19 | Merck & Co Inc | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
CA2439149C (en) | 2001-02-28 | 2012-04-24 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
ES2278016T3 (es) | 2001-04-09 | 2007-08-01 | Novartis Vaccines And Diagnostics, Inc. | Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r). |
US6911447B2 (en) | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
AR043434A1 (es) | 2003-03-03 | 2005-07-27 | Merck & Co Inc | Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos |
CA2519939A1 (en) | 2003-03-26 | 2004-10-14 | Merck & Co., Inc. | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists |
US20050192286A1 (en) | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
US7989634B2 (en) * | 2003-11-12 | 2011-08-02 | Lg Life Sciences Ltd. | Melanocortin receptor agonists |
GB0402492D0 (en) | 2004-02-04 | 2004-03-10 | Pfizer Ltd | Pharmaceutically active compounds |
WO2006019787A2 (en) | 2004-07-16 | 2006-02-23 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
EP1773338B1 (en) | 2004-07-19 | 2010-01-06 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
DE102005000666B3 (de) | 2005-01-04 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US20080234280A1 (en) | 2005-08-01 | 2008-09-25 | Mcmurray Gordon | Use of Mc4 Receptor Agonist Compounds |
JP2009503050A (ja) | 2005-08-04 | 2009-01-29 | ファイザー・リミテッド | ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物 |
BRPI0616463A2 (pt) | 2005-09-29 | 2011-06-21 | Merck & Co Inc | composto, composição farmacêutica, e, uso de um composto |
CA2624031A1 (en) | 2005-09-30 | 2007-04-12 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
EP1940401B1 (en) * | 2005-10-18 | 2012-07-11 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
JP2007131570A (ja) | 2005-11-09 | 2007-05-31 | Mitsubishi Pharma Corp | 新規なアミノピロリジン誘導体 |
MX2008010899A (es) | 2006-02-23 | 2008-11-27 | Pfizer Ltd | Piperidinoilpirrolidinas agonistas del receptor de melanocortina tipo 4. |
WO2007096186A1 (en) | 2006-02-23 | 2007-08-30 | Santhera Pharmaceuticals (Schweiz) Ag | Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators |
CN101466669B (zh) | 2006-06-09 | 2011-11-30 | 阿克申制药公司 | 苯基吡咯氨基胍衍生物 |
TWI332501B (en) | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
AU2007300529A1 (en) | 2006-09-27 | 2008-04-03 | Merck Sharp & Dohme Corp. | Acylated piperidine derivatives as melanocortin-4 receptor modulators |
UA99555C2 (en) * | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
-
2009
- 2009-10-11 UA UAA201105960A patent/UA99555C2/ru unknown
- 2009-11-03 TW TW098137194A patent/TWI389903B/zh not_active IP Right Cessation
- 2009-11-10 JP JP2011536237A patent/JP5399506B2/ja active Active
- 2009-11-10 NZ NZ592512A patent/NZ592512A/xx not_active IP Right Cessation
- 2009-11-10 MX MX2011004583A patent/MX2011004583A/es active IP Right Grant
- 2009-11-10 CN CN200980144988.6A patent/CN102282141B/zh active Active
- 2009-11-10 EP EP09826254.6A patent/EP2350060B1/en active Active
- 2009-11-10 BR BRPI0921063A patent/BRPI0921063B8/pt active IP Right Grant
- 2009-11-10 AU AU2009314827A patent/AU2009314827B2/en active Active
- 2009-11-10 PE PE2011000970A patent/PE20110684A1/es not_active Application Discontinuation
- 2009-11-10 US US13/128,725 patent/US8288386B2/en active Active
- 2009-11-10 CA CA2742248A patent/CA2742248C/en active Active
- 2009-11-10 KR KR1020090108283A patent/KR101141976B1/ko active IP Right Grant
- 2009-11-10 US US12/615,407 patent/US8039622B2/en active Active
- 2009-11-10 WO PCT/KR2009/006568 patent/WO2010056022A2/en active Application Filing
- 2009-11-10 EA EA201170676A patent/EA019146B1/ru unknown
- 2009-11-10 GE GEAP2009012222 patent/GEP20135850B/en unknown
- 2009-11-11 AR ARP090104355A patent/AR074109A1/es active IP Right Grant
- 2009-11-11 UY UY0001032238A patent/UY32238A/es not_active Application Discontinuation
-
2011
- 2011-04-26 IL IL212468A patent/IL212468A0/en unknown
- 2011-04-29 ZA ZA2011/03154A patent/ZA201103154B/en unknown
- 2011-05-03 EC EC2011011026A patent/ECSP11011026A/es unknown
- 2011-05-05 MA MA33818A patent/MA32774B1/fr unknown
- 2011-05-06 TN TN2011000222A patent/TN2011000222A1/fr unknown
- 2011-05-11 CO CO11057597A patent/CO6362006A2/es not_active Application Discontinuation
- 2011-05-12 CR CR20110250A patent/CR20110250A/es unknown
- 2011-05-12 CL CL2011001073A patent/CL2011001073A1/es unknown
- 2011-06-13 US US13/158,734 patent/US8236955B2/en active Active
- 2011-06-13 US US13/158,920 patent/US8183243B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0921063A2 (pt) | Composto, e, composição agonística para o receptor de melanocortina. | |
BRPI0909084A2 (pt) | Composição líquida, e, composto de peptídeo. | |
BRPI1010768A2 (pt) | composto, e, composição farmacêutica. | |
BRPI0906962A2 (pt) | Composto, e, composição farmacêutica | |
BRPI0906556A2 (pt) | Composto, e, composição farmacêutica | |
BRPI0915731A2 (pt) | composição de graxa. | |
BRPI0913447A2 (pt) | composição de éster, e, composição para cuidado pessoal. | |
BRPI0813235A2 (pt) | Combinação anti-helmíntica. | |
BRPI1010301A2 (pt) | composição. | |
BRPI0918433A2 (pt) | combinação herbicida compreendendo difluormetano sulfonilanildas substittuídas por demetoxitriazinila. | |
BRPI0814745A2 (pt) | Composição de produto. | |
BRPI0915732A2 (pt) | composição de graxa. | |
DK1989196T3 (da) | Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister | |
BRPI0815246A2 (pt) | Composição de catalisador | |
BRPI0918637A2 (pt) | composição antimicrobiana. | |
BRPI0917681A2 (pt) | Composto, e, composição farmacêutica | |
FR2937049B1 (fr) | Composition de nettoyage. | |
BR112012003151A2 (pt) | composição de revestimento, e, método. | |
BRPI0807961A2 (pt) | agonista de alfa2c adrenorreceptor funcionalmente seletivos. | |
BRPI0914584A2 (pt) | Método, e, composição herbicida. | |
BRPI0814748A2 (pt) | Compostos de alditóis substituídos, composições e métodos | |
IT1393413B1 (it) | Composizione pesticida. | |
BRPI0912118A2 (pt) | composto, composição farmacêutica, e, intermediário sintético | |
BRPI0918860A2 (pt) | mecanismo manualmente operável para veículo. | |
BRPI0919612A2 (pt) | complexo metálico, composição para uso agrícola, e, utilização de um complexo metálico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: LG LIFE SCIENCES LTD. (KR) |
|
B25G | Requested change of headquarter approved |
Owner name: LG LIFE SCIENCES LTD. (KR) |
|
B25A | Requested transfer of rights approved |
Owner name: LG CHEM, LTD (KR) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/03/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/11/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |